Figure 1 — Reported female:male prevalence (selected diseases)

Data source: Table and text from the reviewed narrative (ratios: SS up to 20:1; SLE ~9:1; HT broadly 4–10:1; others listed) Review — epidemiology table

Figure 2 — Relative emphasis of X‑linked mechanisms in the review

This pie is a qualitative synthesis of emphasis in the review: major focus on genes escaping XCI (TLR7, CXorf21, IRAK1), substantial discussion of skewed XCI influencing immune mosaicism, plus mentions of X‑reactivation and epidemiology of aneuploid karyotypes Review — mechanisms

Critical summary (visual‑first)

• What the paper does well: Integrates epidemiology, cytogenetic observations (47,XXY;47,XXX;45,X) with molecular X‑chromosome biology (XCI, escape, skew) and enumerates X‑linked immune candidates (TLR7, CXorf21/TASL, IRAK1, CD40L, FOXP3, IL2RG), citing experimental and single‑cell studies that find biallelic expression/escape in immune cell subsets Review — strengths
• Main limitations: narrative review design (selection bias risk), limited primary data integration, inconsistent strength of evidence across diseases, and essential gaps: lack of cell‑type resolved, longitudinal human XCI/escape maps during disease onset; limited causal tests (functional perturbations in human immune cells) Review — limitations acknowledged

Detailed critique & external evidence

1) Causal claims vs associative evidence — correct caution: the review repeatedly frames X‑linked hypotheses as plausible but not proven. This restraint aligns with the broader literature that shows sex differences in immune responses are multifactorial (hormones, autosomal genes, environment) and that X‑chromosome mechanisms are plausible contributors but rarely singular causes Nat Rev Immunol — sex differences in immunity

2) TLR7 and escape: the review highlights TLR7 as a leading candidate (escape in B cells, pDCs; gain‑of‑function mutations causing lupus‑like disease in mice). This is consistent with experimental work showing TLR7 dosage increases type I IFN and autoantibody production; however, human causality remains incomplete and tissue/cell resolution varies by study Review — TLR7 evidence

3) XCI skewing hypothesis: mechanistically attractive (mosaic antigen representation → tolerance gaps), but human association studies are mixed (some autoimmune diseases show higher skewing; others do not). The review correctly notes divergent results and the possibility that inflammation and clonal expansion during disease can themselves generate skewing (reverse causation) — an essential blindspot to track in future studies Review — XCI skewing evidence

4) Epigenetic reactivation & immune cell state: the review cites studies where XCI maintenance is perturbed in immune cells from SLE patients and mouse models. Those mechanistic data are compelling but mostly observational or model-based; translating to human disease causation requires perturbation experiments in primary human immune cells and longitudinal sampling around disease onset XCI epigenetics in lupus (preprint)

Practical takeaways and falsification criteria

1. If high‑quality, multi‑center single‑cell allele‑specific expression maps from disease‑relevant immune tissues (salivary glands for SS; kidney and blood for SLE; thyroid for HT) showed no consistent, reproducible female‑biased biallelic expression (escape) for the implicated genes (TLR7, CXorf21, IRAK1) at disease onset, the dosage/escape hypothesis would be weakened.
2. If prospective human studies demonstrated that observed XCI skewing precedes disease onset (i.e., present in healthy at‑risk individuals who later develop disease) that would strengthen causality; if skewing instead consistently arises after inflammation/clonal expansions, that supports reverse causation.
3. Loss‑of‑function or allele‑specific knockdown of escapee genes (e.g., reducing TLR7 biallelic expression) in human primary immune cells that prevents autoimmune phenotypes would be decisive experimental evidence; failure of such manipulations to alter autoimmune activation would disfavor dosage hypotheses.

Recommended next steps (concise, experimental)

• Generate allele‑resolved single‑cell RNA + ATAC from disease tissues and matched blood from early/incident cases and high‑risk individuals to map escape/skew dynamics over time.
• Develop allele‑specific perturbations (CRISPRi targeting promoter/enhancer only on the escape allele) in primary human B cells/pDCs to test whether reducing biallelic expression of TLR7/CXorf21 alters IFN production and autoantibody generation.
• Combine endocrine profiling (estrogen/testosterone), microbiome, and XCI mosaicism measurement to quantify the relative contributions of hormone vs X‑chromosome dosage to immune phenotypes (multi‑omic causal inference).

Key citations used in this analysis

1. Review — X chromosome & autoimmunity
2. Nat Rev Immunol — sex differences
3. XCI epigenetics in lupus (preprint)